Concierge familial-cancer assessment · London
Breast cancer risk assessment, Tyrer-Cuzick, BOADICEA, genetic testing and personalised screening.
A structured personal, family and genetic assessment to estimate lifetime breast cancer risk. Combines Tyrer-Cuzick and BOADICEA (CanRisk) models with BRCA1 / BRCA2 / PALB2 / ATM / CHEK2 testing where indicated — and stratifies women into moderate, high and very-high risk pathways.
Why patients choose us
- 01
The right hands
We route you to a consultant breast or clinical geneticist — the person who assesses you, calculates your risk and plans the pathway.
- 02
Modern models used
Tyrer-Cuzick and BOADICEA (CanRisk) are the standard — used the way NICE CG164 and the UK Cancer Genetics Group intend.
- 03
Independent, and free
We are paid by no clinic, so the recommendation is impartial and costs you nothing.
Indicative pricing
What a private breast cancer risk assessment costs in London.
Indicative ranges across our partner clinics. Send the details and we quote firm figures across two or three options.
In short
A standard risk assessment in our network: £350–£600, with a multi-gene panel typically £750–£1,600.
| Assessment type | Indicative range | Typical duration | Report turnaround |
|---|---|---|---|
| Standard breast risk assessment consultation | £350–£600 | 45 min | Same-day |
| Risk assessment + Tyrer-Cuzick / BOADICEA modelling | £500–£850 | 60 min | Same-day |
| BRCA1 / BRCA2 targeted gene testing | £450–£900 | 30 min | 4–6 weeks |
| Multi-gene panel (BRCA1, BRCA2, PALB2, ATM, CHEK2, others) | £750–£1,600 | 30 min | 4–6 weeks |
| Cascade testing of known family variant | £300–£600 | 30 min | 3–4 weeks |
| Full high-risk pathway (assessment + panel + follow-up) | £1,500–£2,800 | Half-day | 4–6 weeks |
Prices vary by clinic, whether a targeted or multi-gene panel is used, and whether the assessment is bundled with follow-up. We come back with a firm quote within one working day.
The problem
A risk assessment is only as good as who runs it.
The models — Tyrer-Cuzick, BOADICEA (CanRisk) — are only as accurate as the family history that goes into them, and the interpreter reading them. We route you to a consultant breast surgeon or clinical geneticist, not a generalist.
-
Strong family history of breast or ovarian cancer?
We arrange the risk assessment and, where criteria are met, the multi-gene panel.
-
Known BRCA in the family?
We arrange targeted cascade testing — faster and cheaper than a full panel.
-
Ashkenazi Jewish ancestry?
Even with limited family history, targeted BRCA1/2 founder-variant testing is often appropriate.
The journey
From enquiry to report — what happens, in order.
One clinician from first message to report — often within days, with gene-panel results within weeks.
Phase 1 · Before your appointment
Concierge, off-stage for you
Phase 2 · On the day
~45–60 minutes at the clinic
Phase 3 · After
Concierge, back on
- 01
Before
You tell us what’s going on
A short, confidential form. Personal history, family cancer history, referral or insurer if you have them.
- 02
Before
We come back with a recommendation
Within one working day: whether a full risk assessment is the right step, which clinic, indicative price. If cascade testing of a known family variant is the better route, we say so.
- 03
Before
We arrange the appointment
Often within the week, including evenings and Saturdays. Insurer pre-authorisation handled.
- 04
On the day
Detailed history taken
A 3-generation family history is drawn out on the day. Bring what you know — dates, ages at diagnosis, tumour types.
- 05
On the day
The consultation itself
45–60 minutes. Tyrer-Cuzick and BOADICEA calculated in front of you. Multi-gene panel offered if criteria are met.
- 06
On the day
Straight home
No recovery time. If bloods are taken for a gene panel, results follow in 4–6 weeks.
- 07
After
Report and next steps
A written summary with your 10-year and lifetime risk, a personalised screening plan, and — if indicated — an urgent risk-reducing surgery pathway.
Typical end-to-end: 1–2 weeks for the assessment. Gene-panel results: 4–6 weeks.
What it shows
What a breast cancer risk assessment answers.
The assessment answers a specific question — what is my quantified breast cancer risk, and does a high-penetrance gene variant sit behind it. These are the outputs.
-
10-year and lifetime breast cancer risk
A quantified estimate, calibrated by Tyrer-Cuzick and BOADICEA against your history.
-
Ovarian cancer risk (BRCA / BOADICEA)
BOADICEA (CanRisk) also returns an ovarian-cancer lifetime risk — material for BRCA carriers.
-
BRCA1 or BRCA2 pathogenic variant
The high-penetrance genes: a positive result changes screening, surgery and family conversations.
-
PALB2, ATM, CHEK2 variants
Moderate-to-high penetrance genes now routinely reported on multi-gene panels.
-
Variant of uncertain significance (VUS)
A finding of unclear meaning — reported, but does not on its own change management.
-
Family cascade-testing plan
If a pathogenic variant is found, first-degree relatives can be tested for the same variant.
-
Chemoprevention eligibility (tamoxifen, anastrozole)
Whether risk-reducing endocrine therapy is a NICE-supported option for you.
-
Red flag: pathogenic BRCA1/2 variant — urgent risk-reducing surgery pathway
A confirmed BRCA1/2 variant moves you into an urgent multidisciplinary surgery conversation.
Next steps
What the assessment can lead to.
Depending on your calculated risk and any gene finding, one or more of these pathways may open up.
-
Enhanced surveillance (annual MRI + mammogram)
Annual breast MRI from 30 and annual mammography from 35–40 for high-risk women — the NICE CG164 pathway.
-
Chemoprevention (tamoxifen, raloxifene, anastrozole)
Risk-reducing endocrine therapy for eligible moderate- and high-risk women, per NICE.
-
Risk-reducing mastectomy for BRCA1/2
Bilateral mastectomy with reconstruction — a considered choice, not a hurried one.
-
Risk-reducing salpingo-oophorectomy for BRCA1/2
Removal of ovaries and fallopian tubes, typically from 35–40 (BRCA1) or 40–45 (BRCA2).
-
Genetic counselling for family
A separate, dedicated conversation about the implications for children, siblings and parents.
-
Cascade testing of relatives
Targeted single-variant testing for first-degree relatives once a family variant is identified.
-
Lifestyle risk-reduction (weight, alcohol, HRT choices)
The modifiable inputs — weight, alcohol intake, and HRT decisions in the context of your risk.
-
Follow-up in familial-cancer clinic
Ongoing review — the plan is revisited as new family history emerges and as evidence evolves.
Our vetted London network
A small panel of clinics, we picked them.
Partners across central, north, west and south London. Not listed publicly — introductions are made privately, once we understand your case.
Selection criteria
How we choose every clinic in our network.
-
Consultant breast surgeons and clinical geneticists
-
Tyrer-Cuzick and BOADICEA (CanRisk) used as standard
-
UKAS-accredited laboratories for BRCA and multi-gene panels
-
Onward familial-cancer-clinic pathway if a pathogenic variant is found
Safety and eligibility
A conversation and a blood test — not an invasive procedure.
The physical footprint is small. The practical points are what genetic testing means for you and your family, and where the models’ limits are.
-
Non-invasive assessment
The consultation itself is a conversation and a calculation — no scans, no needles. Gene testing needs only a blood sample.
-
A 3-generation family history helps
Bring what you know: relatives with breast, ovarian, prostate or pancreatic cancer, and ages at diagnosis. The more accurate, the better the model.
-
Insurance and genetic testing
The ABI Code on Genetic Testing (2018) means predictive genetic test results do not have to be disclosed for most life insurance.
-
Testing is your choice
You can accept the risk assessment and decline gene testing. You can accept BRCA testing and decline a wider panel.
-
A VUS is not a diagnosis
A variant of uncertain significance is exactly that — it does not, on its own, change your management.
-
Cascade testing is optional
If a variant is found in you, telling relatives is a personal choice — the clinic can help you plan that conversation.
-
Male relatives count
Male breast cancer and prostate cancer at a young age are important family-history signals for BRCA2.
-
A normal panel doesn’t remove all risk
Most familial breast cancer is polygenic — a negative panel does not remove risk from strong family history alone.
-
Bring prior imaging and reports
Previous mammograms, MRI reports and any relative’s genetic-test result materially sharpen the assessment.
Reading your report
A risk-assessment report can look intimidating. It isn’t.
Whatever the finding, the report keeps to the same four parts.
A quiet reminder
The report is written for your doctor, not for you — and that’s normal.
If you would like us to talk you through it before your follow-up, just ask.
- 01 Header
Personal and family history
Your details, the reason for the assessment, and the 3-generation family cancer history that shapes interpretation.
- 02 Modelling
Tyrer-Cuzick and BOADICEA outputs
Your 10-year and lifetime breast (and ovarian, where applicable) cancer risk, from both validated models.
- 03 Findings
Genetic test result, if performed
BRCA1, BRCA2, PALB2, ATM, CHEK2 and other panel genes — pathogenic, likely benign, or variant of uncertain significance.
- 04 Impression
The plan: read this first
Moderate, high or very-high risk — with the concrete next step: surveillance, chemoprevention, or a surgery conversation.
Recognised by major UK insurers
Cover depends on your policy and clinic; we confirm with your insurer before booking.
Frequently asked
Everything we get asked about breast cancer risk assessment.
Quick answers on cost, referrals, gene testing, insurance and what a positive BRCA result means.
-
What is a breast cancer risk assessment?
A structured personal, family and (where indicated) genetic assessment to estimate your lifetime and 10-year risk of breast — and sometimes ovarian — cancer. Tyrer-Cuzick and BOADICEA (CanRisk) are the standard models, with multi-gene panel testing offered when criteria are met.
-
What is the difference between Tyrer-Cuzick and BOADICEA?
Both are validated risk models used in the UK. Tyrer-Cuzick incorporates hormonal and reproductive factors and family history. BOADICEA (delivered through the CanRisk tool) integrates a broader family history, polygenic scores and identified gene variants, and returns both breast and ovarian risk. Many clinics run both.
-
When should I be tested for BRCA1 or BRCA2?
NICE CG164 sets specific criteria — broadly, testing is offered when there is a 10% or greater chance of a pathogenic variant, which typically means a strong family history of early-onset breast, bilateral breast, male breast, ovarian, or triple-negative cancer, or Ashkenazi Jewish ancestry with any of the above.
-
How much does a private breast cancer risk assessment cost in London?
A standard risk assessment is typically £350–£600 in our network; adding Tyrer-Cuzick and BOADICEA modelling raises it, and a multi-gene panel adds £750–£1,600. We confirm firm figures within one working day.
-
Do I need a referral?
Most clinics accept self-referral. We can arrange a fast-track private GP if a formal referral is needed for insurance or onward pathway.
-
What happens if I test positive for a BRCA1 or BRCA2 variant?
You move into a high-risk pathway: annual breast MRI from 30 and annual mammography from 35–40, discussion of risk-reducing mastectomy, and — from 35–40 (BRCA1) or 40–45 (BRCA2) — risk-reducing salpingo-oophorectomy to lower ovarian cancer risk. Cascade testing is offered to first-degree relatives.
-
Will genetic testing affect my life insurance?
Under the ABI Code on Genetic Testing (2018), predictive genetic test results do not have to be disclosed for most life insurance policies below the specified thresholds. Speak to your insurer if the sum assured is very high, or if it is critical-illness cover.
-
What is a variant of uncertain significance (VUS)?
A gene change whose clinical meaning is not yet known. A VUS is reported but does not, on its own, change your management. Many are reclassified as benign over time.
-
Can I have chemoprevention instead of surgery?
For eligible moderate- and high-risk women — including many BRCA carriers who decline surgery — tamoxifen, raloxifene or anastrozole are NICE-supported options that can meaningfully lower breast cancer risk.
-
When should I see a GP urgently instead?
A new discrete breast lump, nipple discharge with blood, nipple retraction, or skin changes are a same-week GP or two-week-wait referral — not a risk assessment. A risk assessment is for asymptomatic women worried about family history.
Related tests
Looking for a different test?
-
Mammography
Standard X-ray imaging of the breasts — screening and diagnostic.
Learn more -
MRI breast
High-sensitivity breast MRI — the surveillance workhorse for high-risk women.
Learn more -
Breast lump (benign)
What benign breast lumps look like, and when to be reassured.
Learn more -
All tests
Browse every test and procedure we arrange.
Learn more -
Endometriosis
Related condition guide.
Learn more -
Menopause
Related condition guide.
Learn more -
Coil IUD IUS Insertion And Removal
Related treatment option.
Learn more -
Colposcopy With Lletz
Related treatment option.
Learn more
In practice, in London
Getting breast cancer risk assessment sorted in London, without the guesswork
With breast cancer risk assessment, the London question is usually about report turnaround and the radiologist reading it — not whether the scan is available. Waiting lists on the NHS for breast cancer risk assessment vary widely by borough and by how the GP letter reads. Privately in London, we can normally offer a slot inside the same week, sometimes within 48 hours if there’s a cancellation. The difference isn’t clinical quality — the consultants are frequently the same faces you’d see on the NHS — it’s the calendar.
A typical private booking for breast cancer risk assessment in London starts with a consultant conversation — sometimes in person on Harley Street or Marylebone, sometimes on video if that suits better. Any imaging or diagnostics happen at a nearby CQC-registered facility, and reports usually land within 24 to 72 hours. The whole loop, from first call to written report, is often done inside a fortnight. For breast cancer risk assessment specifically, the difference between a routine report and a sub-speciality read is where private care earns its keep.
We’re careful about what a private pathway for breast cancer risk assessment can and can’t promise. It can compress a wait, put you in front of a subspecialist quickly, and get a proper report in your hands within a week. It can’t rewrite what the imaging or the bloods say. Setting that expectation up front tends to make the whole experience less stressful.